Dr. Reddy's Laboratories Reports Q1 Profit of $165 Million, Revenue of $997 Million

Dr. Reddy's Laboratories reported a profit of $165 million in its fiscal first quarter, with revenue of $997 million. The company's net income per share was 20 cents.

Dr. Reddy's Laboratories Ltd, a prominent pharmaceutical company, reported a profit of $165 million in its fiscal first quarter, with revenue reaching $997 million. The company's net income per share was 20 cents [1].

The stock, trading under the symbol REDY on the NSE, saw a slight increase of 1.80% to close at 1,259.30 INR on July 2, 2025. The company's stock has been trading within a range of 1,245.20 to 1,262.40 INR over the past day, and its 52-week range is between 1,020.00 to 1,421.49 INR [1].

Dr. Reddy's Laboratories operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products, including biologics. The PSAI segment produces active pharmaceutical ingredients and intermediates, and the Others segment focuses on developing therapies in oncology and inflammation [2].

The company's strong earnings were driven by robust sales in its Global Generics and PSAI segments. The Global Generics segment, which includes the company's biologics business, reported significant growth in revenue and profit. The PSAI segment also contributed to the company's strong financial performance, driven by increased demand for its active pharmaceutical ingredients and contract research services [1].

Analysts have been closely monitoring Dr. Reddy's Laboratories, with several recent updates to their ratings. Macquarie downgraded the stock to Neutral due to concerns about gRevlimid, while Morgan Stanley initiated coverage with an Equalweight rating [3].

The company is expected to announce its quarterly financial results on July 23, 2025, which may impact the stock price. Traders are advised to monitor the latest news and analysis to make informed investment decisions [1].

References:
[1] https://www.investing.com/equities/dr-reddys-laboratories
[2] https://www.investing.com/equities/dr-reddys-laboratories
[3] https://www.investing.com/equities/dr-reddys-laboratories